Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Breast Cancer | Unmet Need | Metastatic Triple-Negative Breast Cancer | US/EU | 2019

Login to access report north_east
Contact sales account_box

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment options and the historic lack of targeted therapies available. The treatment landscape has evolved in recent years with the approval of PARP inhibitors Lynparza and Talzenna for patients with germline BRCA mutations and Tecentriq plus Abraxane for PD-L1-positive patients. Despite the availability of new therapies, significant clinical and commercial opportunity remains for the development of targeted and/or immune-based therapies to improve survival outcomes. Our unmet need module analyzes the key drivers of prescribing and assesses how emerging therapies may capitalize on these opportunities.

Questions Answered

  •  What are the key drivers that are most likely to influence treatment uptake for advanced / metastatic TNBC?
  •  How do current therapies perform on key treatment drivers and goals for advanced / metastatic TNBC?
  • What are the prevailing areas of unmet need and opportunities in advanced / metastatic TNBC?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical therapy in newly diagnosed advanced / metastatic TNBC?

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in May 2019.

Key companies: Roche / Genentech, Celgene, AstraZeneca, Pfizer, Eisai.

Key drugs: Tecentriq, Abraxane, Lynparza, Talzenna, Halaven, Avastin.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
north_east
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an autoimmune condition in which the immune-mediated damage to hair follicles results in patchy or extensive hair loss. AA treatment is evolving rapidly as dermatologists…
north_east
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
north_east
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
north_east
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east